uproleselan + mitoxantrone + etoposide + cytarabine

uproleselan + mitoxantrone + etoposide + cytarabine is an investigational combination regimen used primarily in the treatment of relapsed/refractory acute myeloid leukemia (AML). Uproleselan (GMI-1271) is a novel small molecule antagonist of E-selectin, which disrupts cell adhesion-mediated drug resistance in the bone marrow microenvironment, thereby enhancing the effects of chemotherapy and improving patient outcomes[3][5][9]. Mitoxantrone is a type II topoisomerase inhibitor that interferes with DNA replication; etoposide is also a topoisomerase II inhibitor that induces DNA strand breaks; cytarabine is a nucleoside analog that inhibits DNA synthesis. The combination is studied to both increase the rates of complete remission and reduce chemotherapy-related toxicities such as oral mucositis[3][5][1]. This regimen is typically administered intravenously and has demonstrated promising safety and tolerability profiles in early phase trials for relapsed/refractory AML[3][5][9][1]. The developer of uproleselan is GlycoMimetics; the combination regimen itself is under clinical trial assessment and not yet approved for general use.

Other names

MEC + uproleselanmitoxantrone + etoposide + cytarabine + uproleselan